OncoVista Innovative Therapies, Inc.
OVIT
$0.0001
-$0.0001-50.00%
OTC PK
| 09/30/2015 | 06/30/2015 | 03/31/2015 | 12/31/2014 | 09/30/2014 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -3.34% | 469.88% | 17.67% | 588.24% | 37.65% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 10.67% | 278.24% | 11.21% | 295.33% | -15.52% |
| Operating Income | -10.67% | -278.24% | -11.21% | -295.33% | 15.52% |
| Income Before Tax | -243.78% | -22.72% | 9.73% | -318.49% | 161.51% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -243.78% | -22.72% | 9.73% | -318.49% | 161.51% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -243.78% | -22.72% | 9.73% | -318.49% | 161.51% |
| EBIT | -10.67% | -278.24% | -11.21% | -295.33% | 15.52% |
| EBITDA | -10.63% | -278.21% | -11.35% | -295.33% | 15.32% |
| EPS Basic | -234.29% | -20.58% | 11.27% | -315.52% | 161.76% |
| Normalized Basic EPS | -233.33% | -20.54% | 11.24% | -318.52% | 161.68% |
| EPS Diluted | -234.29% | -20.58% | 11.27% | -315.52% | 161.76% |
| Normalized Diluted EPS | -233.33% | -20.54% | 11.24% | -318.52% | 161.68% |
| Average Basic Shares Outstanding | 6.60% | 1.78% | 1.78% | 0.43% | 0.00% |
| Average Diluted Shares Outstanding | 6.60% | 1.78% | 1.78% | 0.43% | 0.00% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |